We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Synthon Pharmaceuticals Successfully Concluded Phase I Clinical Trial for Trastuzumab
News

Synthon Pharmaceuticals Successfully Concluded Phase I Clinical Trial for Trastuzumab

Synthon Pharmaceuticals Successfully Concluded Phase I Clinical Trial for Trastuzumab
News

Synthon Pharmaceuticals Successfully Concluded Phase I Clinical Trial for Trastuzumab

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Synthon Pharmaceuticals Successfully Concluded Phase I Clinical Trial for Trastuzumab"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

All in vitro and in vivo studies conducted so far showed biosimilar behavior of Synthon’s trastuzumab in comparison with the reference product, Herceptin ® . The outcome of the phase I clinical trial confirmed these results, showing bio-equivalence of Synthon’s trastuzumab to Herceptin ® .

“Trastuzumab is one of the most advanced biopharmaceutical products of Synthon’s pipeline, and is now ready to go into a confirmatory phase III clinical trial in breast cancer patients,” says Rudy Mareel, CEO Synthon. “Biosimilars are to Synthon a serious stepping stone towards the development of biosuperior and truly innovative biological products. We are very excited about our growing portfolio of new biological antiproliferative agents that is well positioned next to our biosimilars.”

Continues Mareel: “We are also making significant progress toward our specialty pharmaceuticals strategy, organized around the key therapeutic areas of multiple sclerosis / auto-immune diseases and oncology. We have a significant pipeline under development in these areas, across all our technological platforms of high quality generics, biosimilars and new biological and chemical entities. We are also capitalizing on the strength of our strategy, as a growing number of renowned companies pursue partnerships with Synthon to support our specialty pharma journey. This confirms our belief in our collaborative model and we remain open to research and commercial partnerships.”

Advertisement